HHS has named Ned Sharpless, MD, as the acting FDA Commissioner after Scott Gottlieb, MD, resigned last week. Gottlieb's resignation sparked worry among pharma makers—especially generic and biosimilar manufacturers.
From our sister brand, Managed Healthcare Executive: As more biosimilar agents are approved by FDA, biologic manufacturers are looking for unique ways to hold on to market share.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%